Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value

by Qing Zhou, Yi-Long Wu
Published 2017-08-01

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

by Shan Su, Yi-Long Wu
Published 2017-08-01

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

by Si-Yang Liu, Yi-Long Wu
Published 2017-07-01

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

by E-E Ke, Yi-Long Wu
Published 2016-06-01

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

by Yi-Chen Zhang, Qing Zhou, Yi-Long Wu
Published 2017-10-01

Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer

by Yang-Si Li, Guang-Ling Jie, Yi-Long Wu
Published 2023-08-01

Molecular residual disease: A new clue for individualized approach in non‐small cell lung cancer

by Jia‐Tao Zhang, Wen‐Zhao Zhong, Yi‐Long Wu
Published 2023-03-01

Emerging therapies for non-small cell lung cancer

by Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
Published 2019-04-01

In Vivo Effects of Free Form Astaxanthin Powder on Anti-Oxidation and Lipid Metabolism with High-Cholesterol Diet.

by Yung-Yi Chen, Pei-Chi Lee, Yi-Long Wu, Li-Yun Liu
Published 2015-01-01

Potential benefited population for sublobar resection

by Rui Fu, MD, Yi-Long Wu, MD, Wen-Zhao Zhong, MD, PhD
Published 2022-12-01

Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives

by Chang Lu, Yi-Chen Zhang, Zhi-Hong Chen, Qing Zhou, Yi-Long Wu
Published 2022-03-01

Predictive value of intra‐tumoural TCRβ rearrangements in precisely selecting adjuvant therapy for EGFR‐mutant non‐small‐cell lung cancer

by Cunte Chen #, Si‐Yang Maggie Liu #, Yi‐Long Wu, Si‐Yang Liu, Yangqiu Li
Published 2022-06-01

Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study

by Jia-Tao Zhang, Si-Yang Liu, Hong-Hong Yan, Yi-Long Wu, Qiang Nie, Wen-Zhao Zhong
Published 2019-11-01

Emerging evidence and treatment paradigm of non-small cell lung cancer

by Si-Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si-Yang Liu, Yangqiu Li, Yi-Long Wu
Published 2023-04-01

Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non–small cell lung cancer: A systematic review and meta-analysisCentral MessagePerspective

by Chao Zhang, MD, Hui-Zhao Hong, MD, Yi-Long Wu, MD, Wen-Zhao Zhong, MD, PhD
Published 2021-12-01

Genomic Evolution of Lung Cancer Metastasis: Current Status and Perspectives

by Wen‐Fang Tang, Rui Fu, Yi Liang, Jie‐Shan Lin, Zhen‐Bin Qiu, Yi‐Long Wu, Wen‐Zhao Zhong
Published 2021-12-01

A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer

by Yichao Han, Si-Yang Maggie Liu, Si-Yang Maggie Liu, Runsen Jin, Wangyang Meng, Yi-Long Wu, Hecheng Li
Published 2023-07-01

Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

by Xue‐Wu Wei, Xin Gao, Xu‐Chao Zhang, Jin‐Ji Yang, Zhi‐Hong Chen, Yi‐Long Wu, Qing Zhou
Published 2020-06-01

Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy

by Jian Su, Yi-Long Wu, Xu-Chao Zhang, Kai Yin, Si-Yang Liu, Li-Xu Yan, Xue-Ning Yang
Published 2021-04-01

Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform

by Hong-Xia Tian, Xu-Chao Zhang, Zhen Wang, Jian-Guang Chen, Shi-Liang Chen, Wei-Bang Guo, Yi-Long Wu
Published 2016-03-01